T- wave axis deviation is associated with biomarkers of low-grade inflammation

Summary

T-wave axis deviation (TDev) may help identifying subjects at risk for major cardiac events and mortality, but the pathogenesis of TDev is not well established; in particular, the possible association between TDev and inflammation is unexplored and unknown. We aimed at investigating the association between low-grade inflammation and TDev abnormalities by conducting a cross-sectional analysis on 17,507 subjects apparently free from coronary heart and haematological diseases enrolled in the MOLI-SANI study. TDev was measured from a standard 12-lead resting electrocardiogram. High sensitivity (Hs) C-reactive protein (CRP), leukocyte (WBC) and platelet counts, neutrophil or granulocyte to lymphocyte ratios were used as markers of inflammation. In multivariable model subjects reporting high CRP levels had higher odds of having borderline and abnormal TDev (OR=1.70; 95 %CI: 1.53–1.90 and OR=1.72; 95 %CI: 1.23–2.41, respectively); the association was still significant, although reduced, after controlling for body mass index (OR=1.17; 95 %CI: 1.05–1.32, for borderline and OR=1.46; 95 %CI: 1.03–2.08, for abnormal). Similarly, higher neutrophil or granulocyte to lymphocyte ratios were associated with increased odds of having abnormal TDev. Neither platelet nor leukocyte counts were associated with abnormal TDev. The relationship between CRP with TDev abnormalities was significantly stronger in men, in non- obese or normotensive individuals, and in those without metabolic syndrome. In conclusion, C-reactive protein and some cellular biomarkers of inflammation such as granulocyte or neutrophil to lymphocyte ratios were independently associated with abnormal TDev, especially in subjects at low CVD risk. These results suggest that a low-grade inflammation likely contributes to the pathogenesis of T- wave axis deviation.

Keywords

T-wave axis deviation - low-grade inflammation - hypertension - obesity - metabolic syndrome

^* MOLI-SANI Study Investigators are listed in the Appendix.

• References

• 1 Rautaharju PM, Nelson JC. et al. Usefulness of T-axis deviation as an independent risk indicator for incident cardiac events in older men and women free from coronary heart disease (the Cardiovascular Health Study). Am J Cardiol 2001; 88: 118e23.
• 2 Kors JA, de Bruyne MC, Hoes AW. et al. T axis as an indicator of risk of cardiac events in elderly people. Lancet 1998; 352: 601-605.
• 3 Assanelli D, Di Castelnuovo A, Rago L. et al. T-wave axis deviation and left ventricular hypertrophy interaction in diabetes and hypertension. J Electrocardiol 2013; 46: 487-491.
• 4 Faramawi MF, Caffrey JL, Amanzadeh J. et al. Cystatin C estimated renal dys-function predicts T wave axis deviation in US adults: results from NHANES III. Eur J Epidemiol 2011; 26: 101-107.
• 5 Rago L, Di Castelnuovo A, Assanelli D. et al. T-wave axis deviation, metabolic syndrome and estimated cardiovascular risk in men and women of the MOLISANI study. Atherosclerosis 2013; 226: 412-418.
• 6 Faramawi MF, Sall M, Abdul Kareem MY. The association of the metabolic syndrome with T-wave axis deviation in NHANES III. Ann Epidemiol 2008; 18: 702e7.
• 7 Barbaresko J, Koch M, Schulze MB. et al. Dietary pattern analysis and biomarkers of low-grade inflammation: a systematic literature review. Nutr Rev 2013; 71: 511-527.
• 8 Ridker PM. High-sensitivity C-reactive protein: potential adjunction for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
• 9 Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc 2001; 285: 2481-2485.
• 10 Emerging Risk Factors Collaboration. Kaptoge S, Di Angelantonio E, Lowe G. et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-140.
• 11 Thaulow E, Erikssen J, Sandvik L. et al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
• 12 van der Bom JG, Heckbert SR, Lumley T. et al. Platelet count and the risk for thrombosis and death in the elderly. J Thromb Hemost 2009; 07: 399-405.
• 13 Campbell PJ, MacLean C, Beer PA. et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 2012; 120: 1409-1411.
• 14 Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. Arterioscler Thromb Vasc Biol 2005; 25: 658-670.
• 15 Rienstra M, Sun JX, Magnani JW. et al. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). Am J Cardiol 2012; 15 (109) 533-537.
• 16 Bonaccio M, Di Castelnuovo A, De Curtis A. et al. Adherence to the Mediterranean diet is associated with lower platelet and leukocyte counts: results from the Moli-sani study. Blood 2014; 123: 3037-3044.
• 17 Bhat T, Teli S, Rijal J. et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 2013; 11: 55-59.
• 18 Di Castelnuovo A, De Curtis A, Costanzo S. et al. Association of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLISANI study. Haematologica 2013; 98: 1476-1480.
• 19 Macfarlane PW, Devine B, Latif S. et al. Methodology of ECG interpretation in the Glasgow program. Methods Inf Med 1990; 29: 354-361.
• 20 Pearson TA, Mensah GA, Alexander RW. et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
• 21 Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
• 22 Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 01: 1897-1905.
• 23 de Gaetano G, Cerletti C, Nanni-Costa MP. et al. The blood platelet as an inflammatory cell. Eur Respir J (Suppl) 1989; 06: 441s-445s.
• 24 Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res 2013; 112: 1506-1519.
• 25 Swirski FK, Robbins CS. Neutrophils usher monocytes into sites of inflammation. Circ Res 2013; 112: 744-745.
• 26 Alagiakrishnan K, Beitel JD, Graham MM. et al. Relation of T-axis abnormalities to coronary artery disease and survival after cardiac catheterization. Am J Cardiol 2005; 96: 639-642.
• 27 Yue W, Schneider A, Rückerl R. et al. Relationship between electrocardiographic and biochemical variables in coronary artery disease. Int J Cardiol 2007; 119: 185-191.
• 28 Visser M, Bouter LM, McQuillan GM. et al. Elevated C-reactive protein levels in overweight and obese adults. J Am Med Assoc 1999; 282: 2131-2135.
• 29 Aronson D, Bartha P, Zinder O. et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004; 28: 674-679.
• 30 Després JP. Inflammation and cardiovascular disease: is abdominal obesity the missing link?. Int J Obes Relat Metab Disord 2003; 27 (Suppl. 03) S22-S24.